The following is a list of scientific abstracts, posters and presentations on our research using the microbiota-based products currently under development in the MRT™ drug platform. Click on the title of the congress publication below to view complete details.
Researching RBX2660 and the Reduction of Clostridioides difficle Infection Recurrence
Improvement of MICROBIOME HEALTH INDEX™ in Patients with Recurrent Clostridiodes difficile Infections Following RBX2660 Treatment is Associated with a Reduction in Antimicrobial Resistance Genes
ASM Microbe 2019
June 20-24, 2019, San Francisco, CA
Response to Microbiota-Based Drug RBX2660 is Associated with Reduction in Antimicrobial Resistance Genes in Patients with Recurrent Clostridiodes difficile Infections
ASM Microbe 2019
June 20-24, 2019, San Francisco, CA
RBX7455 – A Non-frozen, Lyophilized, Oral Microbiota-based Drug Reduces Clostridrium difficile Infection Recurrence and Restores Patients’ Microbiomes
ACG 2018
October 5-10, 2018, Philadelphia, PA
Prevention of Recurrent Clostridium difficile at Six Months Following Treatment with Microbiota-based Therapy RBX2660: Durability Results From a Phase 2 Open-label Study
IDWeek 2018
October 3-7, 2018, San Francisco, CA
Evaluating a Prototype MICROBIOME HEALTH INDEX™ (MHI™) as a Measure of Microbiome Restoration Using Data Derived From Published Studies of Fecal Microbiota Transplant to Treat recurrent Clostridium difficile Infections (rCDI)
IDWeek 2018
October 3-7, 2018, San Francisco, CA
A Prototype Biomarker for Microbiome Rehabilitation in Patients with Clostridium difficile Infections: Application to a Clinical Trial of a Lyophilized, Non-Frozen, Oral, Microbiota-Based Drug RBX7455
ASM Microbe 2018
June 7-11, 2018, Atlanta, GA
Developing Microbiome Rehabilitation Biomarkers for Clostridium difficile Infections: Continued Evaluation of a Prototype MICROBIOME HEALTH INDEX™
Digestive Disease Week (DDW)
June 2-5, 2018, Washington, DC
A Lyophilized, Non-Frozen, Oral Microbiota-Based Drug RBX7455 is Safe, Reduces Clostridium difficile Infection Recurrence, and Restores the Microbiome
Digestive Disease Week (DDW)
June 2-5, 2018, Washington, DC
The Microbiota-based Drug RBX2660 is Efficacious and Safe in Patients with Recurrent Clostridium difficile Infections: Results from 2 Controlled Clinical Trials
28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
April 21-24, 2018, Madrid, Spain
Developing Microbiome Rehabilitation Biomarkers for Clostridium difficile Infections: Evaluation of a Prototype MICROBIOME HEALTH INDEX™
28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
April 21-24, 2018, Madrid, Spain
Altering the Microbiome: Patients with a Successful Outcome Following Microbiota-Based RBX2660 Treatment Trend Toward Human Microbiome Project Healthy Subjects’ Profile
World Congress of Gastroenterology @ ACG 2017
October 13-18, 2017, Orlando, FL
Developing Microbiome Rehabilitation Biomarkers for Clostridium difficileInfections: Evaluation and Plan of a Prototype MICROBIOME HEALTH INDEX™ (MHI™)
World Congress of Gastroenterology @ ACG 2017
October 13-18, 2017, Orlando, FL
There is No Association Between Patient Outcomes and Demographics in an Open-Label Safety and Efficacy Study of RBX2660, a Microbiota-Based Drug for Recurrent Clostridium difficile Infection
World Congress of Gastroenterology @ ACG 2017
October 13-18, 2017, Orlando, FL
RBX2660 is Safe, Superior to Antibiotic-Treated Controls for Preventing Recurrent difficile, and May Rehabilitate Patient Microbiomes: Open Label Trial Results
Infectious Diseases Week (ID Week)
October 4-8, 2017, San Diego, CA
Microbiome Profile is Distinct in Patients with Successful Response to Microbiota-Based Drug RBX2660 Relative to Placebo Responders
Infectious Diseases Week (ID Week)
October 4-8, 2017, San Diego, CA
Successful Response to Microbiota-Based Drug RBX2660 in Patients with Recurrent Clostridium difficile Infection is Associated with More Pronounced Alterations in Microbiome Profile
Infectious Diseases Week (ID Week)
October 4-8, 2017, San Diego, CA
Changing the Microbiome: Patients with a Successful Outcome Following Microbiota-Based RBX2660 Treatment Trend Toward Human Microbiome Project Healthy Subjects’ Profile
ASM Microbe 2017
June 1-5, 2017, New Orleans, LA
Resetting the Microbial Landscape: Donor Microbiome Engraftment in Patients Treated with RBX2660 for Multi-Recurrent Clostridium difficile Infection
ASM Microbe 2017
June 1-5, 2017, New Orleans, LA
Meta-analysis of Response Rates Among Placebo-Treated Patients from Five Clinical Trials of Experimental Recurrent Clostridium difficile Therapeutics
ASM Microbe 2017
June 1-5, 2017, New Orleans, LA
Lack of Association with Patient Demographics and Outcomes in PUNCH CD 2, a Randomized Controlled Trial of RBX2660, a Microbiota-based Drug for Recurrent Clostridium difficile Infection
Digestive Diseases Week
May 6-9, 2017, Chicago, IL
Donors are Universal in the Fight Against Clostridium difficile: Results from Two Trials Investigating the Safety and Efficacy of RBX2660, a Microbiota-based Drug
Digestive Diseases Week
May 6-9, 2017, Chicago, IL
Alterations in Microbial Diversity are Associated with Treatment Success with RBX2660, a Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection: Results from PUNCH CD 2: a Randomized Double-Blind Placebo-Controlled Trial
Digestive Diseases Week
May 6-9, 2017, Chicago, IL
Durable Prevention of Recurrent C. difficile Infection with RBX2660: Results of the PUNCH CD 2 Trial
ACG 2016 Annual Scientific Meeting
October 15-19, 2016, Las Vegas, NV
Placebo Response in a Randomized Controlled Trial of a Microbiota-based Drug Targeted at Recurrent C. difficile Infection: Results of the PUNCH CD 2
ACG 2016 Annual Scientific Meeting
October 15-19, 2016, Las Vegas, NV
Does the Donor Matter? Results from PUNCH CD 2, a Randomized Controlled Trial of a Microbiota-based Drug for Recurrent Clostridium difficile Infection
ACG 2016 Annual Scientific Meeting
October 15-19, 2016, Las Vegas, NV
Efficacy and Safety of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection: Results of the PUNCH CD 2 Trial
Infectious Diseases Week (ID Week)
October 26-30, 2016, New Orleans, LA
Impact of RBX2660 on the Intestinal Microbiota of Patients with Recurrent Clostridium difficile Infection Enrolled in the Randomized, Placebo-Controlled PUNCH CD 2 Trial
Infectious Diseases Week (ID Week)
October 26-30, 2016, New Orleans, LA
Placebo Responders in a Randomised Controlled Trial of RBX2660 for Recurrent C. Difficile Infection: Predictive Value of 16s rRNA Microbiome Analysis
United European Gastroenterology Week
October 15-19, 2016, Vienna, Austria
RBX2660, A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection, Is Safe and Effective: Results from a Randomised, Double-Blinded, Placebo-Controlled Trial
United European Gastroenterology Week
October 15-19, 2016, Vienna, Austria
Consistent and Reproducible Production of a Microbiota-based Drug for Recurrent C. difficile Infection: Application of a Novel Diagnostic for Dysbiosis
United European Gastroenterology Week
October 15-19, 2016, Vienna, Austria
Increased Microbial Diversity Found in Successful Recipients of Next-Generation FMT for Recurrent Clostridium difficile Infection
Gut Microbiota for World Health
March 5-6, 2016, Miami, FL
Infectious Threats in “Healthy” Donors: Results of a Donor Screening Program for a Next-Generation FMT
Gut Microbiota for World Health
March 5-6, 2016, Miami, FL
Increased Microbial Diversity Found in Successful vs. Unsuccessful Recipients of Next-Generation FMT for Recurrent Clostridium difficile Infection
Infectious Diseases Week 2015
October 7-11, 2015, San Diego, CA
Assessing Infectious Threats in “Healthy” FMT Donors: Results of an Assessment Program to Support a Next-Generation Drug for Recurrent Clostridium difficile Infection
Infectious Diseases Week 2015
October 7-11, 2015, San Diego, CA
Successful Implementation of a Phase 2 Study of a Novel Microbiota-based Drug for Recurrent Clostridium difficile Infection
Society of Gastroenterology Nurses and Associates
May 15–19, 2015, Baltimore, MD
Perspectives on the PUNCH CD Trial of a Microbiota-Based Drug Targeted at Recurrent C. difficile Infection
Society of Gastroenterology Nurses and Associates
May 15–19, 2015, Baltimore, MD
Does the Donor Matter? Donor vs. Patient Effects in the Outcome of Next-Generation Fecal Transplant for Recurrent Clostridium difficile Infection
Digestive Diseases Week
May 16–19, 2015, Washington, DC
Clearance of Vancomycin-Resistant Enterococcus Concomitant with Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection
European Congress of Clinical Microbiology and Infectious Diseases
April 25-28, 2015, Copenhagen, Denmark
Results of the Phase 2 PUNCH™ CD Safety Study of RBX2660 (microbiota suspension) for Recurrent C. difficile Infection
European Congress of Clinical Microbiology and Infectious Diseases
April 25-28, 2015, Copenhagen, Denmark
Enema Administration of RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: Lessons Learned from the PUNCH CD Study
American College of Gastroenterology
October 17-20, 2014, Philadelphia, PA
RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study
American College of Gastroenterology
October 17-20, 2014, Philadelphia, PA
Evaluation of Health-Related Quality of Life in Patients Treated with RBX2660 (microbiota suspension) for Recurrent C. difficile Infection
American College of Gastroenterology
October 8-12, 2014, Philadelphia, PA
RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study
Infectious Diseases Week 2014
October 8-12, 2014, Philadelphia, PA
Who Seeks a Fecal Microbiota Transplant for Recurrent C. difficile Infection?: Patient Profile of the PUNCH™ CD Study
Infectious Diseases Week 2014
October 8-12, 2014, Philadelphia, PA
Next Generation Fecal Transplant for Recurrent C. difficile Infection with and without Antibiotic Pre-Treatment: Lessons Learned from the PUNCH CD Phase 2 Safety Study
Infectious Diseases Week 2014
October 8-12, 2014, Philadelphia, PA
Regulatory Considerations in Commercializing a Non-Antibiotic Microbiota-Based Drug Targeted for Recurrent Clostridium difficile Infection
Microbiome / Microbiota
R&D and Business Collaboration Forum
October 2-3, 2014, San Diego, CA